What is Tibet Weixinkang Medicine Co., Ltd.'s (603676.SS) StockRank?

MoatMap's StockRank for Tibet Weixinkang Medicine Co., Ltd. (603676.SS) is 83/100, with a Strong Buy signal. This is a composite score combining Quality (80), Value (49), and Momentum (41) factor ranks across MoatMap's 20,000+ stock universe.

Does Tibet Weixinkang Medicine Co., Ltd. have an economic moat?

Tibet Weixinkang Medicine Co., Ltd. (603676.SS) has a Quality factor score of 80/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Tibet Weixinkang Medicine Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Tibet Weixinkang Medicine Co., Ltd. (603676.SS) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Tibet Weixinkang Medicine Co., Ltd. in?

Tibet Weixinkang Medicine Co., Ltd. (603676.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603676.SS

STRONG BUYREMOVE

Tibet Weixinkang Medicine Co., Ltd. · Healthcare · China · $594M · Avg Vol: $2M/d

StockRank

P/E (TTM)

17.6x

ROE

14.4%

D/E

0.0x

Dividend %

3.6%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Tibet Weixinkang Medicine is a Chinese pharmaceutical company. It lacks global scale, does not fit the CDMO pricing power cycle, and is highly exposed to domestic regulatory and pricing risks in China.

COMPANY DESCRIPTION

Tibet Weixinkang Medicine is a specialty pharmaceutical company focusing on the research, development, and sale of clinical nutrition products, particularly multi-vitamin and mineral intravenous infusions. The company maintains a strong competitive moat through its dominant market share in China's pediatric and adult multi-vitamin infusion sectors, supported by high clinical barriers and strong hospital channel penetration. It is characterized by its highly focused product portfolio and robust academic marketing capabilities.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	207M	195M	192M	168M	-6.7%
EPS	0.06	0.07	0.08	0.08	9.6%
Shares	435M	435M	435M	435M	0.0%
Debt	856,140	1M	778,605	2M	24.6%
Equity	180M	198M	205M	218M	6.5%
Op CF	36M	36M	55M	27M	-9.0%
Inv CF	16M	-58M	-31M	-3M	—
Fin CF	-11M	-15M	-32M	-25M	—

PRICE (1M)-18.1%

SMA 50SMA 200

$1.29

RSI (14)

36.9

52W High

$2.18

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

18.7%90.3

ROE

14.4%81.5

GP/Assets

38.2%77.3

Op. Margin

24.0%87.5

FCF/Assets

3.7%64.9

Piotroski

—83.4

Int. Cover

50.0x91.4

D/E Ratio

0.01x90.5

Current Ratio

3.74x61.6

Value

P/E (TTM)

17.6x64.5

EV/EBITDA

11.3x38.3

P/FCF

394.9x19.7

P/B

2.5x47.2

P/S

3.3x53.8

Div Yield

3.6%79.8

Momentum

52W High %

59%38.5

RS 6M

-31%40.4

SMA 50/200

0.90x35.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+78%65.6

Q Growth

-19%25.3

FUNDAMENTALS

Market Cap

$594M

P/E (Forward)

9.9x

Gross Margin

61.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603676.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603676.SS	Tibet Weixinkang Medicine Co., Ltd.(you)	$594M	83	STRONG BUY
0719.HK	Shandong Xinhua Pharmaceutical Company Limited	$533M	84	STRONG BUY
6998.HK	Edding Genor Group Holdings Limited	$509M	81	STRONG BUY
600976.SS	Jianmin Pharmaceutical Group Co.,Ltd.	$690M	87	STRONG BUY
002393.SZ	Tianjin Lisheng Pharmaceutical Co.,Ltd.	$679M	90	STRONG BUY
002349.SZ	Jinghua Pharmaceutical Group Co., Ltd.	$866M	85	STRONG BUY
002390.SZ	Guizhou Xinbang Pharmaceutical Co., Ltd.	$870M	81	STRONG BUY
603367.SS	Cisen Pharmaceutical Co., Ltd.	$934M	81	STRONG BUY
1349.HK	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.	$317M	81	STRONG BUY
603207.SS	Shanghai Xiao Fang Pharmaceutical Co.,Ltd.	$556M	70	BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Tibet Weixinkang Medicine Co., Ltd. (603676.SS) — Stock Score Summary

Tibet Weixinkang Medicine Co., Ltd. (603676.SS) has a MoatMap StockRank of 83/100 based on Quality (80/100), Value (49/100), and Momentum (41/100) factor scores. The current signal is STRONG BUY. Tibet Weixinkang Medicine is a Chinese pharmaceutical company. It lacks global scale, does not fit the CDMO pricing power cycle, and is highly exposed to domestic regulatory and pricing risks in China.

Key Financial Metrics

Price	$1.29
Market Cap	$594M
P/E (TTM)	17.64
P/E (Forward)	9.91
Price/Book	2.47
Return on Equity	14.4%
Return on Invested Capital	18.7%
Debt/Equity	0.77
Gross Margin	61.1%
Operating Margin	24.0%
Revenue Growth	8.9%
Dividend Yield	3.6%
Free Cash Flow	$2M

Tibet Weixinkang Medicine Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Tibet Weixinkang Medicine Co., Ltd.’s (603676.SS) StockRank?: MoatMap’s StockRank for Tibet Weixinkang Medicine Co., Ltd. (603676.SS) is 83/100, with a Strong Buy signal. It is a composite of Quality (80), Value (49), and Momentum (41) factor ranks across MoatMap’s 20,000+ stock universe.
Does Tibet Weixinkang Medicine Co., Ltd. have an economic moat?: Tibet Weixinkang Medicine Co., Ltd. (603676.SS) has a Quality factor score of 80/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tibet Weixinkang Medicine Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Tibet Weixinkang Medicine Co., Ltd. (603676.SS) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tibet Weixinkang Medicine Co., Ltd. in?: Tibet Weixinkang Medicine Co., Ltd. (603676.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).